Edward T. Mathers
Edward T. Mathers's purchase track record
How the stock did after each of Edward T. Mathers's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/10/2026 | KRRO | $2.30M | -4.7% | +17.7% | +13.2% |
| 2/9/2026 | SGP | $15.00M | -9.2% | -3.9% | +11.3% |
| 9/16/2024 | MBX | $8.00M | -11.6% | -59.1% | +0.8% |
| 4/22/2024 | KRRO | $1000K | -29.3% | +10.9% | +16.8% |
| 7/17/2023 | SVRA | $1000K | +11.8% | +35.7% | +5.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Korro Bio Begins Phase 1/2 Trial for KRRO-121. Korrr Bio has begun dosing the first cohort of its Phase 1/2 study for KRRO-121, a therapy aimed at treating hyperammonemia in patients with urea cycle disorders. The initiation of this trial marks a significant milestone in the drug’s development timeline. Analysts continue to hold a $15 price target, reflecting confidence in the program. Current technical data shows the stock trading near its 52‑week low with an RSI of 39.7.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
SpyGlass Pharma Schedules Upcoming Investor Conference Participation. SpyGlass Pharma has announced its participation in upcoming investor conferences, a routine corporate engagement where company leadership typically meets with institutional investors and analysts to discuss business performance and outlook. The stock is currently trading near the upper end of its 52-week range of $17.06 to $32.44, with the average analyst price target standing at $44.00 based on six analyst estimates. Technical indicators show elevated momentum readings alongside a recent Bollinger band breakout, reflecting recent market interest in the pharmaceutical company's shares.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
MBX Biosciences to Attend Investor Conferences, Analyst Target Raised. MBX Biosciences will join several investor conferences in November, offering a chance for investors to hear about its pipeline. Stifel has kept a positive stance and lifted its target price to $84. Analysts are debating whether the recent 257% jump has pushed the stock above fair value, while others question if the pullback from a strong year run still leaves room for upside.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Savara Stock Mentioned Among Gainers in Market Roundup. Savara Inc. was included in a recent market roundup highlighting stocks that moved higher on Wednesday. The company's shares are currently trading near a key support level, which may have contributed to the short-term price movement noted in the report. This mention reflects general market activity rather than a specific corporate announcement.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
TRVI releases Q2 2026 earnings and makes Raymond James top health list. Trevi Therapeutics held its Q2 2026 earnings call, sharing the latest financial and operational results. In a separate note, Raymond James analysts listed the stock among their top four healthcare picks. The earnings discussion and analyst endorsement may draw additional attention to the company. The shares are trading close to the upper end of their 52‑week range.
Transaction History
| RYTM | ▼ Sell | Other | 4,199 | $0 | 3/12/2026 | View on chart |
| KRRO | ▲ Buy | Open Market | 207,100 | $2.3M | 3/10/2026 | View on chart |
| RYTM | ▼ Sell | Other | 4,198 | $0 | 3/2/2026 | View on chart |
| SGP | ▼ Sell | Other | 1,619,240 | — | 2/9/2026 | View on chart |
| SGP | ▼ Sell | Other | 1,370,168 | — | 2/9/2026 | View on chart |
| SGP | ▼ Sell | Other | 737,962 | — | 2/9/2026 | View on chart |
| SGP | ▼ Sell | Other | 1,370,168 | — | 2/9/2026 | View on chart |
| SGP | ▲ Buy | Open Market | 937,500 | $15.0M | 2/9/2026 | View on chart |
| OKUR | ▲ Buy | Grant | 3,911 | $0 | 12/31/2025 | View on chart |
| OKUR | ▲ Buy | Grant | 4,125 | $0 | 9/30/2025 | View on chart |
| OKUR | ▲ Buy | Grant | 4,694 | $0 | 6/30/2025 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 4,000 | — | 6/18/2025 | View on chart |
| OKUR | ▲ Buy | Grant | 2,580 | $0 | 3/31/2025 | View on chart |
| MBX | ▼ Sell | Other | 1,023,103 | — | 9/16/2024 | View on chart |
| MBX | ▼ Sell | Other | 2,091,383 | — | 9/16/2024 | View on chart |
| MBX | ▲ Buy | Open Market | 500,000 | $8.0M | 9/16/2024 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 3,000 | — | 6/21/2024 | View on chart |
| KRRO | ▲ Buy | Open Market | 17,857 | $1000K | 4/22/2024 | View on chart |
| SVRA | ▲ Buy | Open Market | 333,333 | $1000K | 7/17/2023 | View on chart |
| RYTM | ▼ Sell | Other | 5,771 | $0 | 3/2/2023 | View on chart |
| TRVI | ▲ Buy | Grant | 948,948 | $1.8M | 4/11/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
RYTM: RBC raises price target to $159, maintains Outperform
RBC Capital kept its Outperform rating on Rhythm Pharmaceuticals and lifted its price target to $159. The new target sits well above the stock’s 52‑week high of $122.20 and higher than the consensus analyst target of $138.59. A recent Benzinga piece also highlighted the stock’s five‑year total return, underscoring its past performance. These developments may influence market perception of the company’s growth prospects.
RYTM: RBC raises price target to $159, maintains Outperform. RBC Capital kept its Outperform rating on Rhythm Pharmaceuticals and lifted its price target to $159. The new target sits well above the stock’s 52‑week high of $122.20 and higher than the consensus analyst target of $138.59. A recent Benzinga piece also highlighted the stock’s five‑year total return, underscoring its past performance. These developments may influence market perception of the company’s growth prospects.